Chagas disease - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Chagas disease – Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Chagas disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Chagas disease: Overview
Chagas disease, also known as American trypanosomiasis, is a potentially life-threatening illness caused by the protozoan parasite Trypanosoma cruzi. About 6 million to 7 million people worldwide are estimated to be infected with T. cruzi, the parasite that causes Chagas disease. The disease is found mainly in endemic areas of 21 continental Latin American countries, where it is mostly transmitted to humans and other mammals by contact with faeces or urine of triatomine bugs (vector-borne), known as 'kissing bugs', among many other popular names, depending on the geographical area. Chagas disease presents itself in two phases. The initial acute phase lasts for about two months after infection. During the acute phase, a high number of parasites circulate in the blood but in most cases, symptoms are absent or mild and unspecific. During the chronic phase, the parasites are hidden mainly in the heart and digestive muscle. Up to 30% of patients suffer from cardiac disorders and up to 10% suffer from digestive (typically enlargement of the oesophagus or colon), neurological or mixed alterations. Chagas disease can be treated with benznidazole and also nifurtimox.
'Chagas disease - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chagas disease pipeline landscape is provided which includes the disease overview and Chagas disease treatment guidelines. The assessment part of the report embraces, in depth Chagas disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chagas disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Chagas disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chagas disease Emerging Drugs
Further product details are provided in the report
Chagas disease: Therapeutic Assessment
This segment of the report provides insights about the different Chagas disease drugs segregated based on following parameters that define the scope of the report, such as:
Chagas disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chagas disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chagas disease drugs.
Chagas disease Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Chagas disease – Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Chagas disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Chagas disease: Overview
Chagas disease, also known as American trypanosomiasis, is a potentially life-threatening illness caused by the protozoan parasite Trypanosoma cruzi. About 6 million to 7 million people worldwide are estimated to be infected with T. cruzi, the parasite that causes Chagas disease. The disease is found mainly in endemic areas of 21 continental Latin American countries, where it is mostly transmitted to humans and other mammals by contact with faeces or urine of triatomine bugs (vector-borne), known as 'kissing bugs', among many other popular names, depending on the geographical area. Chagas disease presents itself in two phases. The initial acute phase lasts for about two months after infection. During the acute phase, a high number of parasites circulate in the blood but in most cases, symptoms are absent or mild and unspecific. During the chronic phase, the parasites are hidden mainly in the heart and digestive muscle. Up to 30% of patients suffer from cardiac disorders and up to 10% suffer from digestive (typically enlargement of the oesophagus or colon), neurological or mixed alterations. Chagas disease can be treated with benznidazole and also nifurtimox.
'Chagas disease - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chagas disease pipeline landscape is provided which includes the disease overview and Chagas disease treatment guidelines. The assessment part of the report embraces, in depth Chagas disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chagas disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Chagas disease R&D. The therapies under development are focused on novel approaches to treat/improve Chagas disease.
This segment of the Chagas disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chagas disease Emerging Drugs
- Fosravuconazole: Seren Pharmaceuticals
Further product details are provided in the report
Chagas disease: Therapeutic Assessment
This segment of the report provides insights about the different Chagas disease drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Chagas disease
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Chagas disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chagas disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chagas disease drugs.
Chagas disease Report Insights
- Chagas disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Chagas disease drugs?
- How many Chagas disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chagas disease?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chagas disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chagas disease and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Chagas disease: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Chagas disease – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Chagas disease companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Chagas disease Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Fosravuconazole: Seren Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical stage products
Comparative Analysis
Chagas disease vaccine: ConserV Bioscience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Chagas disease Key Companies
Chagas disease Key Products
Chagas disease- Unmet Needs
Chagas disease- Market Drivers and Barriers
Chagas disease- Future Perspectives and Conclusion
Chagas disease Analyst Views
Chagas disease Key Companies
Appendix
Executive Summary
Chagas disease: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Chagas disease – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Chagas disease companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Chagas disease Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Fosravuconazole: Seren Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical stage products
Comparative Analysis
Chagas disease vaccine: ConserV Bioscience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Chagas disease Key Companies
Chagas disease Key Products
Chagas disease- Unmet Needs
Chagas disease- Market Drivers and Barriers
Chagas disease- Future Perspectives and Conclusion
Chagas disease Analyst Views
Chagas disease Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Chagas disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Chagas disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Chagas disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Chagas disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
